Angiodynamics Looks To Overcome Legal Woes, Regain Momentum
This article was originally published in The Gray Sheet
Executive Summary
Angiodynamics' plan to sidestep patent infringement concerns relating to its VenaCure laser system for varicose veins could help boost sales growth and lift the cloud over the firm's stock performance after a poor showing in the first quarter
You may also be interested in...
Varicose vein treatment patent case heads to trial
VNUS Medical Technologies' patent infringement case against competitors Diomed, AngioDynamics and Vascular Solutions is scheduled to go to trial Oct. 29 in the U.S. District Court in Northern California following the judge's denial of both sides' motions for summary judgment Oct. 2. VNUS, maker of the ClosureFAST radiofrequency system for treatment of varicose veins, alleged infringement of patents related to the technology in 2005. AngioDynamics replaced its VenaCure product with a modified NeverTouch VenaCure system in June after losing a separate patent suit to Diomed, maker of the EVLT endovenous laser treatment. Vascular Solutions also modified its Vari-Lase system as a result of that case (1"The Gray Sheet" April 16, 2007, p. 16)
Varicose vein treatment patent case heads to trial
VNUS Medical Technologies' patent infringement case against competitors Diomed, AngioDynamics and Vascular Solutions is scheduled to go to trial Oct. 29 in the U.S. District Court in Northern California following the judge's denial of both sides' motions for summary judgment Oct. 2. VNUS, maker of the ClosureFAST radiofrequency system for treatment of varicose veins, alleged infringement of patents related to the technology in 2005. AngioDynamics replaced its VenaCure product with a modified NeverTouch VenaCure system in June after losing a separate patent suit to Diomed, maker of the EVLT endovenous laser treatment. Vascular Solutions also modified its Vari-Lase system as a result of that case (1"The Gray Sheet" April 16, 2007, p. 16)
Given Imaging’s Japan Reimbursement Drives 45% Stock Gain In 2nd Quarter
Given Imaging's receipt of Japanese marketing and reimbursement clearance for its flagship PillCam SB ingestible video capsule endoscope system helped propel a 45.5% stock price jump in the second quarter